Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...

Jefferies Financial Group started coverage on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research report ...

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including ...

Fintel reports that on April 7, 2025, Jefferies initiated coverage of Axsome Therapeutics (NasdaqGM:AXSM) with a Buy ...

Schroder Investment Management Group decreased its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 58.6% in the fourth quarter, according to its most recent 13F filing with ...

Jefferies initiated coverage of Axsome Therapeutics (AXSM) with a Buy rating and $200 price target The company currently markets three central ...

CNS specialist Axsome Therapeutics has announced results from the PARADIGM Phase III proof-of-concept trial of solriamfetol ...

It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...

After Axsome Therapeutics (AXSM) yesterday reported negative results from its Phase 3 major depressive disorder trial evaluating Sunosi as a ...

Axsome Therapeutics, Inc. has announced the topline results of the Paradigm Phase 3 proof-of-concept trial of Solriamfetol in major depressive disorder (MDD) with and without excessive daytime ...

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Shares of biopharmaceutical company Axsome Therapeutics (NASDAQ: AXSM) had declined 6% at 11 a.m. ET today. The slump comes ...